NKTR
Nektar Therapeutics · Healthcare
Insiders sold $2.4M of Nektar Therapeutics in the last 12 months and bought none
NKTR over the last year
NKTR after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Every filing
259 insider filings since 2016, newest first
Howard W Robin · President and CEO
Jonathan Zalevsky · Chief R&D Officer
Howard W Robin · President and CEO
Jonathan Zalevsky · Chief R&D Officer
Howard W Robin · President and CEO
Howard W Robin · President and CEO
Jonathan Zalevsky · Chief R, D Officer
Jonathan Zalevsky · Chief R, D Officer
Mark Andrew Wilson · General Counsel
Howard W Robin · President and CEO
Howard W Robin · President and CEO
Deep Track Capital, LP · 10% owner
Jonathan Zalevsky · Chief R, D Officer
Jillian B. Thomsen · CFO
Howard W Robin · President and CEO
Jonathan Zalevsky · Chief R, D Officer
Mark Andrew Wilson · General Counsel
Jillian B. Thomsen · CFO
Howard W Robin · President and CEO
Karin Eastham · Director
Jonathan Zalevsky · Chief R, D Officer
Jonathan Zalevsky · Chief R, D Officer
Howard W Robin · President and CEO
Jonathan Zalevsky · Chief R, D Officer
Howard W Robin · President and CEO
Gil M Labrucherie · SVP, COO and CFO
Jonathan Zalevsky · Chief R, D Officer
Mark Andrew Wilson · SVP and General Counsel
Jillian B. Thomsen · SVP and Chief Accounting Officer
Howard W Robin · President and CEO
John Northcott · SVP and Chief Commercial Officer
Gil M Labrucherie · SVP, COO and CFO
Gil M Labrucherie · SVP, COO and CFO
Jonathan Zalevsky · Chief R, D Officer
Mark Andrew Wilson · SVP and General Counsel
Jillian B. Thomsen · SVP and Chief Accounting Officer
Howard W Robin · President and CEO
John Northcott · SVP and Chief Commercial Officer
Myriam Curet · Director
Robert Chess · Director
Jeffrey Robert Ajer · Director
Robert Chess · Director
Jonathan Zalevsky · Chief R, D Officer
Mark Andrew Wilson · SVP and General Counsel
Howard W Robin · President and CEO
Jillian B. Thomsen · SVP and Chief Accounting Officer
John Northcott · SVP and Chief Commercial Officer
Gil M Labrucherie · SVP, COO and CFO
Robert Chess · Director
Jonathan Zalevsky · Chief R, D Officer
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.